Craif raised $33 million in a Series D to support U.S. clinical trial development for its urine-based pancreatic cancer assay, with the company preparing a U.S. laboratory scale-up in San Diego. The program centers on miSignal Dx Pancreatic Cancer, which computes a risk score from microRNA expression in urine exosome samples. Craif said it aims to prepare for Japan’s PMDA submission as well, while pursuing CLIA certification and reimbursement strategy via the CMS MolDx program. The clinical plan calls for about 500 high-risk participants and targets an interim readout in 12–18 months, with full trial completion afterward. For the early detection field, the financing reflects continued momentum behind noninvasive biomarker platforms and their push from pilot performance toward clinical utility evidence.